# Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis

> **NCT07190391** · — · NOT_YET_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 425 (estimated)

## Conditions studied

- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07190391
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 425 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190391, "Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07190391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*